Back to Results
Sheeona Gorman, PhD
Department + Services
Institute for Clinical Research and Health Policy Studies (ICRHPS), JHU-Tufts Trial Innovation Center (TIC)
Project management, clinical trials
1. Clusterin and Chemotherapy Sensitivity under Normoxic and Graded Hypoxic Conditions in Colorectal Cancer. Kevans D, Gorman S, Tosetto M, Sheahan K, O'Donoghue D, Mulcahy H, O'Sullivan J. J Gastrointestinal Cancer 2011.
2. Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro. Prencipe M, Fitzpatrick P, Gorman S, Tosetto M, Klinger R, Furlong F, Harrison M, O'Connor D, Roninson IB, O'Sullivan J, McCann A. British Journal Cancer 2010.
3. Mitochondrial mutagenesis induced by tumor-specific radiation bystander effects. Gorman S, Fox E, O'Donoghue D, Sheahan K, Hyland J, Mulcahy H, Loeb LA, O'Sullivan J. Journal Molecular Medicine 2010.
4. Radiation and chemotherapy bystander effects induce early genomic instability events: telomere shortening and bridge formation coupled with mitochondrial dysfunction. Gorman S, Tosetto M, Lyng F, Howe O, Sheahan K, O'Donoghue D, Hyland J, Mulcahy H, O'Sullivan J. Mutation Research 2009.
5. Do radiation induced bystander effects correlate to the intrinsic radiosensitivity of individuals and have clinical significance? Howe O, O'Sullivan J, Nolan B, Vaughan J, Gorman S, Clarke C, McClean B, Lyng FM. Radiat Res. 2009.
6. Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis. Coss A, Tosetto M, Fox EJ, Sapetto-Rebow B, Gorman S, Kennedy BN, Lloyd AT, Hyland JM, O'Donoghue DP, Sheahan K, Leahy DT, Mulcahy HE, O'Sullivan JN. Cancer Lett. 2009.
7. Cigarette Smoking in Inflammatory Bowel Disease: Cell Cycle arrest may explain the divergent effects in Crohn’s Disease and Ulcerative Colitis. Garret Cullen, Miriam Tosetto, Sheeona Gorman, Hugh Mulcahy, Diarmuid P O’Donoghue, Jacintha O’Sullivan. Gastroenterology 2008.
Sheeona Gorman, PhD is project director for the NCATS funded Trial Innovation Center (TIC) at Tufts Medical Center. The Johns Hopkins-Tufts TIC is one of three TICs in the NCATS Trial Innovation Network which will develop innovative trial practices and provide expertise and support to improve the efficiency and quality of multisite clinical trials within the CTSA program network.
Previously, Sheeona was a program manager at the Royal College of Surgeons in Ireland (RCSI) where she coordinated international multidisciplinary research programs funded by the European Commission and national funding agencies worth over $50M in the areas of connected health, assistive technology, advanced imaging and biophotonics. She has served on a number of consortium planning committees including the European Molecular Imaging Doctoral School (EMIDS) and the European Strategy Forum for Research Infrastructures (ESFRI).
Prior to joining RCSI, Sheeona worked in ICONplc as a project manager where she managed a portfolio over 15 Phase I-IV clinical trials for major pharmaceutical companies. Sheeona earned her BSc (Hons) degree in biochemistry from the National University of Ireland Galway and received a PhD from University College Dublin which focused on molecular mechanisms driving genomic instability in response to radiotherapy in colorectal cancer.